EJX Stock Chart & Stats
€4.82
€0.00(0.00%)
At close: 4:00 PM EDT
€4.82
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€3.98 - €5.70
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€1.89B
Enterprise Value€2.42B
Total Cash (Recent Filing)€2.30B
Total Debt (Recent Filing)€6.81B
Price to Earnings (P/E)―
Beta0.32
Next Earnings
Nov 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.98
Shares Outstanding368,587,650
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)2.92
Price to Sales (P/S)1.26
P/FCF Ratio8.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationStrong operating and free cash flow gives Elekta internal funding capacity despite reported losses. TTM free cash flow growth of 18.5% and solid cash conversion can support service delivery, product investment, and balance-sheet resilience over coming quarters.
Cost Savings And Margin ImprovementThe completed operating-model change and savings above SEK 500m indicate a durable effort to lower the cost base. Combined with higher gross and EBIT margins, this can improve earnings quality and provide operating leverage if sales stabilize.
Recurring Service GrowthGrowth across the service business supports the recurring portion of Elekta’s revenue model and helps offset variability in capital-equipment orders. A growing installed-base service stream can improve revenue visibility and support margins over the medium term.
Bears Say
Severe Revenue And Profitability DeclineThe sharp TTM revenue contraction and return to net losses show that recent cost actions have not yet restored overall earnings power. Thin operating profitability and negative returns weaken financial resilience and leave future performance dependent on a sustained revenue recovery.
China Market And Pricing PressureElekta is facing a structural challenge in China as weaker prior orders reduce installations and procurement becomes more centralized. Lower estimated market share and increased price transparency could constrain both volume growth and pricing power in an important region.
Higher Leverage And Negative ReturnsLeverage has risen materially from historical levels while returns on equity have turned negative. This combination reduces financial flexibility, increases the importance of restoring profitability, and may constrain Elekta’s ability to fund investment or absorb prolonged operating weakness.
Elekta AB News
EJX FAQ
What was Elekta AB’s price range in the past 12 months?
Elekta AB lowest stock price was €3.98 and its highest was €5.70 in the past 12 months.
What is Elekta AB’s market cap?
Elekta AB’s market cap is €1.89B.
When is Elekta AB’s upcoming earnings report date?
Elekta AB’s upcoming earnings report date is Nov 25, 2026 which is in 42 days.
How were Elekta AB’s earnings last quarter?
Elekta AB released its earnings results on Aug 27, 2026. The company reported €0.063 earnings per share for the quarter.
Is Elekta AB overvalued?
According to Wall Street analysts Elekta AB’s price is currently Overvalued.
Does Elekta AB pay dividends?
Elekta AB does not currently pay dividends.
What is Elekta AB’s EPS estimate?
Elekta AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Elekta AB have?
Elekta AB has 368,587,650 shares outstanding.
What happened to Elekta AB’s price movement after its last earnings report?
Elekta AB reported an EPS of €0.063 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Elekta AB?
Currently, no hedge funds are holding shares in DE:EJX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Elekta AB Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
11.95%
12-Months-Change
Fundamentals
Return on Equity
-4.66%
Trailing 12-Months
Asset Growth
-6.37%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Elekta AB
Elekta AB (publ) is a global medical technology company dedicated to developing and delivering advanced clinical solutions for the treatment of cancer and brain disorders. Its comprehensive portfolio includes innovative radiotherapy systems such as the Elekta Unity MR-Linac, the Elekta Harmony linear accelerator, Elekta Infinity for diverse patient radiotherapy requirements, and the Elekta Synergy digital accelerator for advanced image-guided radiation therapy. Specific solutions like Versa HD are available for managing brain metastases. The company also supplies crucial treatment management software, automated and integrated quality assurance tools, and hardware and software for motion management. Further augmenting its oncology offerings, Elekta provides MOSAIQ Plaza for integrated multidisciplinary cancer care and Elekta Axis Cloud for managed hosting. Within brachytherapy, key products include the image-guided Elekta Studio, the mobile ImagingRing CT scanner, Oncentra Brachy for streamlining repetitive tasks, the Elekta Flexitron afterloader for precise workflow execution, and specialized applicators like Venezia and Geneva for cervical cancer treatment. For neurological conditions, Elekta offers a suite of advanced radiosurgery and neurosurgery solutions. This includes the Leksell Gamma Knife series – Icon for personalized radiation treatment, Perfexion for neurosurgical applications, and Lightning for accelerated procedures. Its neurosurgery product line features the Leksell Vantage Stereotactic System for intracranial interventions and the Leksell Stereotactic System for minimally invasive stereotactic neurosurgery. Founded in 1972, Elekta maintains its corporate headquarters in Stockholm, Sweden.
EJX Company Deck
EJX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced picture: strong execution on cost savings and clear improvements in margins and cash generation provided encouraging evidence that the company’s turnaround is underway. However, top‑line challenges remain — net sales declined, solutions sales were weak, China and APJ showed regional softness, rolling orders lagged and working capital rose. Management reaffirmed FY guidance and expects Q2 revenue improvement driven by backlog and U.S. product momentum. Overall the company appears to be stabilizing and improving profitability while still working through material revenue and regional challenges.View all DE:EJX earnings summariesTechnical Analysis
Accuray
―
Perspective Therapeutics
―
Koninklijke Philips
―
Varex Imaging
―
GE Healthcare Technologies Inc
―